IMR Press / EJGO / Volume 30 / Issue 2 / pii/2009031

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours

Show Less
1 School of Anatomy and Human Biology, University of Western Australia, Crawley, (Switzerland)
2 Department of Radiation Oncology, Sir Charles Gairdiner Hospital, Ned/ands (Switzerland)
3 King Edward Memorial Hospital for Women, Perth (Switzerland)
4 Department of Paediatric Pathology, Princess Margaret Hospital, Subiaco, Perth, and School of Women and Infant Health, University of Western Australia, Crawley (Switzerland)
5 School of Anatomy & Human Biology, University of Western Australia, Crawley, Perth (Switzerland)
6 Department of Clinical Research, University of Berne, Berne (Switzerland)
7 Department of Radiation Oncology, Sir Charles Gairdiner Hospital, Hospital Avenue, Nedlands, Western Australia (Australia)
Eur. J. Gynaecol. Oncol. 2009, 30(2), 133–141;
Published: 10 April 2009
Abstract

Objective: Serous ovarian cancer is the most prevalent type of ovarian cancer. The majority of women present at an advanced stage and patient survival is poor. Resistance to chemotherapy is thought to relate to failure of tumours to undergo apoptosis. Secreted frizzled-related protein 4 (SFRP4) has been demonstrated to be involved in apoptosis in the ovary but not in ovarian tumours as yet. This study examined SFRP4 expression in ovarian cancers and correlated this with expression of β-catenin, a main component of the wNT-signalling pathway it inhibits. Methods: We examined 153 primary serous ovarian carcinomas for SFRP4 and B-catenin expression using immunohistochemistry on tissue microarrays and correlated this with clinical information. Results: SFRP4 expression was inversely associated with beta-catenin expression in 84% of samples. However, high-level SFRP4 expression was not significantly associated with patient survival (p = 0.08). Conclusion: Elevated SFRP4 expression in serous ovarian tumours appears to correlate with reduced beta-catenin expression but long-term survival appears unaffected by this.

Keywords
Ovary
Carcinoma
Tissue microarray
SFRP4
Immunohistochemistry
β-catenin
Share
Back to top